Sterile Fill-Finish & Aseptic Manufacturing CDMOs
87 published
87 published CDMOs match Sterile Fill-Finish & Aseptic Manufacturing.
Locations in this set include United States, United Kingdom, China, Germany, India, and France.
Capabilities that show up most often in this set: Biologics (Other), Small Molecule, Biologics (Monoclonal Antibodies), Gene Therapy, and Vaccine.
Matching companies
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Unither PharmaceuticalsGlobal CDMO specializing in sterile and non-sterile liquid manufacturing, including Blow-Fill-Seal (BFS) single-dose technology with over 5 billion annual capacity, plus formulation development, analytical services, and ophthalmic expertise across six production sites.
Vetter PharmaIndependent CDMO specialist in aseptic fill-finish, drug product development, analytical services, and combination product assembly with 76 years of experience and 7,300+ employees globally.
Wheeler BioOklahoma-based CDMO specializing in antibody-based therapeutics from cell line development through cGMP manufacturing. Offers ModularCMC platform with phase-appropriate work packages and high-touch project management.
WuXi XDCWuXi XDC is a leading CRDMO offering integrated discovery, development, and cGMP manufacturing services for antibody drug conjugates (ADCs) and bioconjugates, with proximately located facilities that reduce development timelines and costs.
Yapan BioYapan Bio provides integrated process development, characterization, and GMP manufacturing for vaccines, monoclonal antibodies, gene therapy, and viral vector-based biologics, with capabilities up to 1000L bioreactor scale and BSL-2+ containment.
eXmoor PharmaIntegrated cell and gene therapy CDMO with 20+ years of consultancy expertise, offering end-to-end CMC support from early-phase strategy through GMP manufacturing across viral vectors, autologous/allogeneic cell therapies, and RNA technologies.
Markdown mirror: /services/sterile-fill-finish.md